Virginia Contract Research Organization (Shanghai) Co., Ltd. (hereafter referred to as “VCRO (Shanghai)”) has established strategic business partnerships with 7 leading CROs in mainland China, including (in alphabetical order):
Beijing Hengxin Boen Medical Technology Co., Ltd.
Beijing Kenuode Pharmaceutical Co., Ltd
Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd.
Beijing Zhiying Huizhong Medical Technology Co., Ltd.
GEM FLOWER PHARMA TECHNOLOGY
GX pharma technology(beijing)Co.,Ltd
R&G PharmaStudies Co., Ltd
VCRO (Shanghai) aims to lead Chinese corporate customers to break into the international market with their new drugs and medical devices, with core competencies in three main areas: Investigational New Drug (IND) joint application for China and the USA, clinical development of cell therapy, and Software as a Medical Device (SaMD) registration.
VCRO (Shanghai) was invested and established in China, Shanghai, in 2020 by Virginia Contract Research Organization Co., Ltd., a long-established CRO in Taiwan since 1997. VCRO (Shanghai) is committed to providing a full range of high-quality services, of international standards, in the clinical development for new drugs and new medical devices, as well as strategizing clinical plans in three regions including China, the USA and Taiwan. As a leading CRO in Taiwan, VCRO is renowned for its high-quality services in Taiwan and the USA, and has accumulated over 24 years of extensive experience. Not only has VCRO accomplished over 500 projects in both new drugs and medical devices, VCRO has also attained nearly 40 US FDA IND achievements, including new chemical drugs, botanicals, biologics, and 505b2 drugs. In recent years, VCRO has successfully submitted several cell therapy INDs for phases I to III clinical trials and has achieved nearly 100% approval rate. In the aspect of software devices, after the US FDA announced the SaMD (Software as a Medical Device) regulations at the end of 2017, VCRO immediately launched SaMD registration and consultation services in 2018, and has now accumulated over 20 SaMD projects. Regardless of whether the demand is based on the clinical development of SaMD or regarding registration application, VCRO has comprehensive expertise and extensive experience to serve as a competent and reliable partner for SaMD product developers. VCRO applies its 24 years of clinical development experience in new drugs/medical devices and extensive, contemporary scientific knowledge and its practical application, with discernible achievements in over 500 cases, and comprehensive regulatory strategies in China, the United States and Taiwan, to tailor a project plan that adapts our services to support each client’s clinical development needs and expedite their products’ time to market.
VCRO (Shanghai) has partnered with elite Chinese CROs to provide a customer-centric, one-stop service by combining both parties’ regulatory expertise of the US FDA and NMPA, respectively. VCRO (Shanghai) is committed to offering the best clinical development strategies in joint application for China and the USA to our clients by providing synchronized and localized services with no cultural and language barriers.
VCRO (Shanghai) will strive to expand partnership with high-quality business strategy partners to extend our service locations to support our mission in satisfying our clients’ needs; and together, we can attain the goal of launching new drugs and medical devices globally and achieving the core value of improving health for all mankind.
Beijing Hengxin Boen Medical Technology Co., Ltd.
Beijing Kenuode Pharmaceutical Co., Ltd
Beijing YEEDOZENCOM Healthcare Science & Technology Co., Ltd.
Beijing Zhiying Huizhong Medical Technology Co., Ltd.
.png)
GEM FLOWER PHARMA TECHNOLOGY
GX pharma technology(beijing)Co.,Ltd
R&G PharmaStudies Co., Ltd
